New York, NY - (ACCESSWIRE) - 11/12/2013 - Equity Profile Report initiates its NASDAQ Active Stock Weekly Watch List adding Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Dendreon Corp. (NASDAQ:DNDN), Hanwha SolarOne Co., Ltd (NASDAQ:HSOL) and Orexigen Therapeutics, Inc. (NASDAQ:OREX)
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients closed up in its previous session (+10.78%) on 13,130,452 shares traded after Glancy Binkow & Goldberg announced a December 9, 2013 Lead Plaintiff Deadline in the Class Action Lawsuit Against ARIAD Pharmaceuticals, Inc. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) is currently up (+21.4%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.
To find out what other Investors are saying about Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=ARIA&SubId=AW
Dendreon Corp. (NASDAQ:DNDN) a biotechnology company that engages in the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients closed down in its previous session (-2.72%) on 3,188,379 shares traded as Dendreon is to Host Conference Call today November 12 to announce Third Quarter Financial Results. Dendreon Corp. (NASDAQ:DNDN) is currently down (-66.2%) from its recent 52-week high, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.
To find out what other Investors are saying about Dendreon Corp. (NASDAQ:DNDN)Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=DNDN&SubId=AW
Hanwha SolarOne Co., Ltd (NASDAQ:HSOL) an investment holding company that engages in the manufacture and sale of silicon ingots, silicon wafers, photovoltaic cells, and PV modules closed down in its previous session (-1.36%) on 2,653,629 shares traded after Hanwha SolarOne Co., Ltd announced that it will release its unaudited financial results for the third quarter of 2013 before the market opens today, Tuesday, November 12, 2013. Hanwha SolarOne Co., Ltd (NASDAQ:HSOL) is currently down (-12.98%) from its recent 52-week high, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.
To find out what other Investors are saying about Hanwha SolarOne Co., Ltd (NASDAQ:HSOL)Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=HSOL&SubId=AW
Orexigen Therapeutics, Inc. (NASDAQ:OREX) a biopharmaceutical company that focuses on the development of pharmaceutical product candidates for the treatment of obesity closed up in its previous session (+1.20%) on 1,064,126 shares traded after Orexigen and Takeda Announced Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta. Orexigen Therapeutics, Inc. (NASDAQ:OREX) is currently up (+31.2%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.
To find out what other Investors are saying about Orexigen Therapeutics, Inc. (NASDAQ:OREX)Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=OREX&SubId=AW
Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.Timing is important when trading Small Caps and Penny Stocks.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.Equityprofilereport.comDisclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.
Contact Info:Equity Profile Report
[email protected]